

Key abstracts accepted by ASH include:

Medicine or Disease State	Abstract Title	Abstract Number/ Presentation Details
Scemblix	Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study	Abstract #475 Oral Presentation Sunday, December 8 9:30 – 11:00 AM PT
Scemblix	Efficacy and Safety of Asciminib in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Results from the Phase 2 ASC2ESCALATE Trial in the Cohort of Patients (Pts) after 1 Prior Tyrosine Kinase Inhibitor (TKI)	Abstract #479 Oral Presentation Sunday, December 8 9:30 – 11:00 AM PT
Scemblix	Asciminib Shows High Efficacy and Favorable Tolerability at 80 Mg Once Daily and 40 Mg Twice Daily in Patients with Chronic Phase Chronic Myelogenous Leukemia Previously Treated with 2 or More Tyrosine Kinase Inhibitors: Primary Analysis from the ASC4OPT Study	Abstract #4526 Poster Presentation Monday, December 9 6:00 – 8:00 PM PT
Scemblix	Treatment with Asciminib as a Second Line after One Prior Tyrosine Kinase Inhibitor (TKI) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP)– a Chart Review Study in the United States	Abstract #3812 Poster Presentation Sunday, December 8 6:00 – 8:00 PM PT
Ianalumab (VAY736)	A Phase 2 Study of Ianalumab in Patients with Primary Immune Thrombocytopenia Previously Treated with at Least Two Lines of Therapy: Interim Results from VAYHIT3	Abstract #710 Oral Presentation Monday, December 9 10:30 AM – 12:00 PM PT
Rapcabtagene autoleucel (YTB323)	Rapcabtagene Autoleucel (YTB323) in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Phase II Trial Clinical Update	Abstract #67 Oral Presentation Saturday, December 7 9:30 – 11:00 AM PT
Fabhalta®	Oral Iptacopan Monotherapy Leads to Long-Term Improvements in Patient (Pt)-Reported Health-Related Quality of Life (HRQoL) and Investigator-Assessed Signs and Symptoms of Paroxysmal Nocturnal Hemoglobinuria (PNH): 48-Week (Wk) Results from the Phase III APPLY-PNH and APPOINT-PNH Trials	Abstract #4079 Poster Presentation Monday, December 9 6:00 – 8:00 PM PT
Fabhalta	The Effect of Oral Iptacopan Monotherapy on Hematological Parameters in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Is Consistent Regardless of the Type of Prior Anti-C5 Treatment Received: A Post Hoc Analysis of 24-Week Data from the Randomized Phase III APPLY-PNH Trial	Abstract #4087 Poster Presentation Monday, December 9 6:00 – 8:00 PM PT
Fabhalta	Baseline Characteristics of Individuals with Paroxysmal Nocturnal Hemoglobinuria in an App-Based Home-Reported Outcomes Study to Evaluate Disease Burden	Abstract #2327 Poster Presentation Saturday, December 7 5:30 – 7:30 PM PT
Pelabresib (CPI-0610)	Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor–Naïve Patients with Myelofibrosis	Abstract #3178 Poster Presentation Sunday, December 8 6:00 PM - 8:00 PM PT

Key abstracts accepted by SABCS include:

Medicine or Disease State	Abstract Title	Abstract Number/ Presentation Details
Kisqali® (ribociclib)*	Distant disease-free survival (DDFS) across key subgroups from the phase 3 NATALEE trial of ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) in patients with HR+/HER2- early breast cancer (EBC)	Abstract #P4-09-22 Poster Session Thursday, December 12 5:30 – 7:30 PM CST
Kisqali	Impact of ribociclib dose reduction on efficacy in patients with hormone receptor– positive/human epidermal growth factor receptor 2–negative (HR+/HER2-) early breast cancer (EBC) in NATALEE	Abstract #P1-11-16 Poster Session Wednesday, December 11 12:30 – 2:00 PM CST

Kisqali	Risk of recurrence in real-world (RW) NATALEE- and monarchE-eligible populations of patients with HR+/HER2-early breast cancer (EBC) in an electronic health record (EHR)-derived database	Abstract #P2-12-02 Poster Session Wednesday, December 11 5:30 – 7:00 PM CST
Kisqali	Tolerability of First-Line (1L) Treatment (tx) With Ribociclib (RIB) for Metastatic Breast Cancer (MBC) Using 2 Large US Data Sources	Abstract #P3-10-14 Poster Session Thursday, December 12 12:30 – 2:00 PM CST
Kisqali	Impact of body mass index (BMI) on the safety and efficacy of ribociclib (RIB) in patients (pts) with HR+/HER2-advanced breast cancer (ABC): pooled analysis of the MONALEESA (ML)-2, -3, and -7 trials	Abstract #P2-09-20 Poster Session Wednesday, December 11 5:30 – 7:00 PM CST
Kisqali	First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in clinically aggressive HR+/HER2- advanced breast cancer (ABC): a subgroup analysis of RIGHT Choice by intrinsic subtype & gene & signature expression	Abstract #PS2-06 Poster Presentation Thursday, December 12 7:00 – 8:30 AM CST